Jawbone's UP2 device
Some 20 percent of investors said they expect Jawbone to go public this year, according to a Rock Health survey of 43 investors. Jawbone has raised an estimated $725 million, the seed fund reported.
Rock Health released the survey just a few weeks after activity tracker company Fitbit filed the initial paperwork that puts it on the path for an IPO. In the company's filing...
Google-backed 23andMe is finally relaunching its mail-order personal genome service -- just not in the United States. Instead, the company is launching in England, which has a different regulatory framework than the United States.
"These products are considered to be in the lowest risk category and so there is no requirement for any premarket assessment," a spokesperson for the Medications and...
Google's genomics browser, from a video the company released last year.
Between contact lenses for diabetes, big data baseline health studies, and a tiny pill that scans for cancer (not to mention curing death and setting up telemedicine visits based on search results), Google is casting a wide net in the health care field. But the company's biggest contributions might come in an area where...
Once again, Google has captured the news cycle with the announcement of an ambitious, health-focused project. But although Google's health portfolio continues to grow, its handful of health projects are still little more than pet projects to the search giant.
As reported last week by The Wall Street Journal, the Google Baseline study will use a combination of genetic testing and digital health...
This week the increasingly crowded tech event SXSWi descended on Austin, Texas, and -- much more so than in years past -- it has had a prominent health and fitness bent. Below are a few excerpts from health and fitness-related reporting coming out of SXSW:
South by Southwest Boost Health-Care Focus: "As we're seeing people spin out of Facebook, Google and Twitter, we are seeing a real...
This week, MobiHealthNews wrote about Misfit Shine raising funds, FDA clearance for Sense4Baby and eMotion ECG, and some changes to Medicare and Medicaid telemedicine coverage. But some other big names have been writing about digital and mobile health this week too, whether its weighing in on big stories like 23andMe's face-off with the FDA or exploring how doctors are using apps as clinical...
23andMe's app.
In a public letter dated November 22, the Food and Drug Administration has instructed personal genome startup 23andMe to immediately stop selling its testing service until the offering receives de novo 510(k) clearance. Regulatory Focus first spotted the letter.
"[M]onths after you submitted your 510(k)s and more than 5 years after you began marketing, you still had not...
UC Irvine researcher Gene Tsudik (Photo by Steve Zylius)
A team led by University of California-Irvine researchers has developed what's been called an Android-based smartphone paternity test. The app would allow two people, if they had access to their digitized genomes, to run a paternity test comparing their genomes, determine how closely related they are, and even scan their genome for...
Digital health incubator Rock Health has released it's 2012 year in review report, and it shows that venture capital investment in digital health is robust, if still tentative by some measures. Overall investment is up, but a large percentage of the numbers are accounted for by a few big deals and a few big investors.
Venture capitalists invested $1.4 billion in digital health in 2012, a 45...
At the TEDMED event here in San Diego this week, personal genomics company 23andMe co-founder Anne Wojcicki announced that the company now had more than 30,000 "active" genomes in its database and that it would soon launch a "Relative Finder" service for its users.
As part of the new service, users can explore connections to other users of the site to determine how related they are to each other...
.jpeg?itok=HF3iI7dj "Person answering their front door and getting a delivery from another person")
